Fraction I-IV-1 precipitation of immunoglobins from plasma

Patent metadata

Field	Value
Publication number	US-9782477-B2
Application number	US-201313776448-A
Country	US
Kind code	B2
Filing date	Feb 25, 2013
Priority date	Feb 23, 2012
Publication date	Oct 10, 2017
Grant date	Oct 10, 2017

Abstract

Among other aspects, the present invention provides methods for the manufacture of blood protein compositions from pooled plasma. In one embodiment, the invention provides an alcohol fractionation scheme that allows for significant increases in the yield of blood proteins purified from the starting plasma sample. In a specific embodiment, a method for fractionating pooled plasma is provided, the method comprising an initial low pH, high alcohol precipitation step. The present invention also provides pharmaceutical compositions of therapeutic blood proteins.

First claim

What is claimed is:

1. A method for manufacturing an enriched immunoglobulin composition, the method comprising the steps of:
(a) co-precipitating immunoglobulins and alpha-1-antitrypsin (A1PI) from a Cohn pool in a first alcohol precipitation step by adding ethanol to the Cohn pool to a final ethanol concentration of from 20% to 30% (v/v) at a pH of from 5.0 to 6.0, thereby forming a first precipitate comprising the precipitated A1PI and the precipitated immunoglobins and a first supernatant, wherein the first precipitate contains at least 85% of the A1PI content of the Cohn pool;
(b) separating the first precipitate from the first supernatant;
(c) solubilizing immunoglobulins in the separated first precipitate, thereby forming a first suspension having a soluble portion comprising the solubilized immunoglobulins and an insoluble portion comprising insolubilized A1PI; and
(d) separating the soluble portion of the first suspension from the insoluble portion of the first suspension thereby forming an enriched immunoglobulin composition,
wherein the Cohn pool is not contacted with ethanol prior to step (a).

2. The method of claim 1 , wherein the final ethanol concentration is 25±4%.

3. The method of claim 1 , wherein the final ethanol concentration is 25±3%.

4. The method of claim 1 , wherein the final ethanol concentration is 25±2%.

5. The method of claim 1 , wherein the final ethanol concentration is 25±1%.

6. The method of claim 5 , wherein the final ethanol concentration is 25%.

7. The method of claim 1 , wherein the pH is 5.5±0.4.

8. The method of claim 7 , wherein the pH is 5.5±0.3.

9. The method of claim 7 , wherein the pH is 5.5±0.2.

10. The method of claim 7 , wherein the pH is 5.5±0.1.

11. The method of claim 7 , wherein the pH is 5.5.

12. The method of claim 1 , wherein the pH is maintained for the duration of the first alcohol precipitation step.

13. The method of claim 1 , wherein the first alcohol precipitation step comprises adding the alcohol by diffuse addition.

14. The method of claim 13 , wherein the diffuse addition comprises spraying.

15. The method of claim 1 , wherein the first alcohol precipitation step comprises adding the alcohol at a site adjacent to an impeller.

16. The method of claim 1 , wherein the first alcohol precipitation step is performed at a temperature of from −3° C. to −10° C.

17. The method of claim 16 , wherein the first alcohol precipitation step is performed at a temperature of from −5° C. to −9° C.

18. The method of claim 1 , wherein the first precipitate is suspended with from 4 L to 60 L of buffer per kg precipitate.

19. The method of claim 18 , wherein the first precipitate is suspended with from 8 L to 15 L of buffer per kg precipitate.

20. The method of claim 1 , wherein the first suspension has a pH of from 4.0 to 5.4.

21. The method of claim 1 , wherein the first suspension has a pH of from 4.7 to 5.1.

22. The method of claim 1 , wherein the first suspension has a conductivity of from 0 mS/cm to 4 mS/cm.

23. The method of claim 1 , wherein the first suspension has a conductivity of from 0.5 mS/cm to 2 mS/cm.

24. The method of claim 1 , wherein the first precipitate is suspended in a buffer comprising acetate and/or phosphate.

25. The method of claim 1 , wherein the soluble portion of the first suspension is separated from the insoluble portion of the first suspension by centrifugation or filtration.

26. The method of claim 1 , wherein the step of separating the soluble portion of the first suspension from the insoluble portion of the first suspension comprises:
mixing finely divided silicon dioxide (SiO 2 ) with the first suspension, thereby forming a treated suspension; and
separating the SiO 2 from the treated suspension.

27. The method of claim 26 , wherein the finely divided silicon dioxide (SiO 2 ) has an average surface area of from 350 m 2 /g to 410 m 2 /g.

28. The method of claim 26 , wherein the finely divided silicon dioxide (SiO 2 ) is added to the first suspension at a final concentration of from 15 g/kg first precipitate to 80 g/kg first precipitate.

29. The method of claim 1 , wherein the method comprises the steps of:
(a) co-precipitating immunoglobulins and A1PI from the Cohn pool in the first precipitation step by adding ethanol to the Cohn pool to a final ethanol concentration of from 24% to 26% at a pH of from 5.3 to 5.7 and temperature of between −6° C. and −8° C., thereby forming the first precipitate comprising the precipitated A1PI and the precipitated immunoglobulins and the first supernatant;
(b) separating the first precipitate from the first supernatant;
(c) solubilizing the immunoglobulins in the separated first precipitate, thereby forming the first suspension having a soluble portion comprising the solubilized immunoglobulins and an insoluble portion comprising insolubilized A1PI,
(d) treating the first suspension with finely divided silicon dioxide (SiO 2 ), thereby forming a treated suspension;
(e) separating the soluble fraction of the treated suspension from the insoluble fraction of the treated suspension and SiO 2 , thereby forming an enriched immunoglobulin composition.

30. The method of claim 1 , wherein the enriched immunoglobulin composition contains at least 90% of the immunoglobulin content of at least one immunoglobulin class present in the Cohn pool used in step (a).

31. The method of claim 30 , wherein the enriched immunoglobulin composition contains at least 95% of the immunoglobulin content of at least one immunoglobulin class present in the Cohn pool used in step (a).

32. The method of claim 30 , wherein the immunoglobulin class is IgG.

33. The method of claim 1 , wherein the method further comprises the steps of:
(f) precipitating immunoglobulins from the enriched immunoglobulin composition in a second precipitation step, thereby forming a second precipitate and a second supernatant;
(g) suspending the second precipitate to form a second suspension having a soluble portion comprising immunoglobulins and an insoluble portion; and
(h) recovering the soluble fraction of the second suspension, thereby forming a further enriched immunoglobulin composition.

34. The method of claim 33 , wherein the second precipitation step is an alcohol precipitation step.

35. The method of claim 34 , wherein the alcohol precipitation step comprises adding ethanol to the enriched immunoglobulin composition to a final concentration of between 22% and 28% ethanol at a pH between 6.5 and 7.5.

36. The method of claim 34 , wherein the second precipitation step comprises adding the alcohol by diffuse addition.

37. The method of claim 36 , wherein the diffuse addition comprises spraying.

38. The method of claim 34 , wherein the second precipitation step comprises adding the alcohol at a site adjacent to an impeller.

39. The method of claim 34 , wherein the second precipitation step is performed at a temperature between −3° C. and −10° C.

40. The method of claim 33 , wherein the enriched immunoglobulin composition contains at least 90% of the immunoglobulin G content present in the Cohn pool used in step (a).

4

Assignees

• Baxalta Inc
• Baxalta GmbH

Inventors

• Bruckschwaiger Leopold
• Gundinger Thomas
• Nuernberger Julia
• Teschner Wolfgang
• Schwarz Hans-Peter

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title